The All Wales Medicines Strategy Group started the assessment of ivacaftor (Kalydeco) as soon as the drug company formally engaged with the appraisal process. This process is recognised to be robust and normally takes about 21 weeks to allow all parties, including patient organisations such as the Cystic Fibrosis Trust, to submit their comments. The final appraisal decision for Kalydeco is scheduled to be reached at a public meeting on 8th May 2013.
More top news
The Welsh Conservative leader and the Welsh Secretary will today address their party's UK conference in Manchester.
A five-day celebration of LGBT short films will begin this evening in Cardiff.
People who smoke or are overweight may have to go on stop-smoking or weight loss programmes before having some routine operations.